Events

SHERIDAN, WYOMING - December 15, 2025 - XPENG AEROHT has completed a public manned flight of its modular flying car, the "Land Aircraft Carrier," in Dubai and signed purchase agreements totaling 600 flying cars across the Middle East, as the company accelerates overseas expansion and rebrands as ARIDGE.

Dubai manned flight pairs technology validation with commercial traction
The October 12 milestone combined a fully manned demonstration flight with what the company described as record-breaking regional demand, lifting total global orders to over 7,000. The event was witnessed by regional dignitaries, members of the local Chinese community, and more than 100 media outlets, signaling both regulatory interest and market visibility as the "low-altitude economy" shifts from concept showcases to procurement discussions.

SHERIDAN, WYOMING - December 15, 2025 - XPENG AEROHT has secured a manned aircraft special flight permit from the UAE's General Civil Aviation Authority (GCAA) for its modular flying car "Land Aircraft Carrier" in Ras Al Khaimah, enabling manned flight tests across the country and marking a notable step in the overseas commercialization of China's low-altitude eVTOL technology.

Aviation permission becomes a market-entry signal for advanced air mobility
The permit, granted in Ras Al Khaimah, is positioned as the first such authorization obtained by a Chinese flying car company overseas. For B2B stakeholders-from mobility operators to public-sector agencies-regulatory access is often the gating factor that turns "future mobility" narratives into measurable pilots, procurement conversations, and infrastructure planning.

SHERIDAN, WYOMING - December 15, 2025 - XPENG AEROHT, the flying car affiliate of Chinese EV maker XPENG, has begun trial production at what it describes as the world's first intelligent factory for mass-produced flying cars-an operational milestone as next-generation mobility moves from prototypes to industrial output.

Trial production signals a commercialization inflection point
The company started trial production on November 3, 2025, positioning the facility as a bridge between engineering validation and repeatable manufacturing. For the broader eVTOL and "low-altitude mobility" ecosystem, factory readiness matters because it shifts the discussion from flight demonstrations to supply chains, quality systems, and scalable assembly-areas that typically determine whether new vehicle categories can reach customers on schedule.

SHERIDAN, WYOMING - December 15, 2025 - Shanghai is sharpening its push to become a leading center for merger-and-acquisition activity, as the 2025 Mergers and Acquisitions Finance Conference spotlighted stronger regional deal momentum and unveiled a new market index intended to track China's evolving M&A environment.

Policy momentum behind listed-company restructuring
The conference took place as Shanghai marks one year since releasing a three-year action plan aimed at supporting M&A among listed firms. In practical terms, the message to corporate leaders and capital providers is clear: policy alignment and financial-market infrastructure are being positioned to support more transactions that improve efficiency, accelerate industrial upgrading, and strengthen competitiveness in key sectors.

SHERIDAN, WYOMING - December 11, 2025 - The FDA's first use of its new Commissioner's National Priority Voucher (CNPV) has gone not to a cutting-edge biologic, but to a decades-old extended-release antibiotic, Augmentin XR-sending a clear signal that domestic manufacturing and supply resilience are now front-and-center regulatory priorities for the U.S. pharmaceutical industry.

A New Fast-Track Tool Aimed at Supply Chain Security

Launched in June, the CNPV program promises to compress review timelines from the usual 10-12 months to as little as 1-2 months for drugs that align with U.S. "national priorities," such as strengthening domestic production or addressing systemic shortages. The first approval under this framework went to USAntibiotics' Augmentin XR after the FDA completed its review in "just two months," focusing heavily on quality, manufacturing and facility assessments rather than new clinical data.

SHERIDAN, WYOMING - December 11, 2025 - A new convergence of obesity dealmaking, regulatory uncertainty at the U.S. Food and Drug Administration (FDA) and fresh neurology data out of the Clinical Trials on Alzheimer's Disease (CTAD) conference is forcing biopharma executives to recalibrate their 2026 playbooks across R&D, partnering and risk management.

Obesity Dealflow Enters a More Competitive, High-Stakes Phase

Pfizer continues to double down on cardiometabolic disease, following its $10 billion acquisition of obesity startup Metsera with an exclusive collaboration to license YaoPharma's oral GLP-1 receptor agonist YP05002. Together with other emerging oral and peptide GLP-1s, this next wave of assets is pushing obesity beyond a single-product, single-modality market and into a diversified, highly competitive landscape.

SHERIDAN, WYOMING - December 11, 2025 - Saol Therapeutics is turning an FDA rejection into a potential regulatory test case, as the biotech prepares to argue that its pyruvate dehydrogenase complex deficiency (PDCD) drug SL1009 is the ideal "poster child" for the agency's new Rare Disease Evidence Principles (RDEP) framework at a Type A meeting on December 18.

Saol Recasts a Complete Response Letter as a Strategic Opening

On September 8, Saol disclosed that the FDA had issued a complete response letter (CRL) for SL1009, an oral formulation of sodium dichloroacetate for children with PDCD, a genetic disorder affecting fewer than 1,000 people in the U.S. The CRL, according to CEO Dave Penake, "suggested that we would need to do an additional adequate and well controlled clinical trial," and that "and that's not feasible to be done by our company and in this patient population."

SHERIDAN, WYOMING - December 11, 2025 - Terns Pharmaceuticals is rapidly emerging as a serious contender in chronic myeloid leukemia (CML), after early clinical data for its allosteric BCR/ABL1 inhibitor TERN-701 more than doubled response rates seen with Novartis' approved STAMP inhibitor Scemblix in comparable settings and sent the biotech's share price sharply higher.

Best-in-Disease Early Efficacy Raises the Bar in CML

At the American Society of Hematology (ASH) annual meeting, Terns reported Phase I data from the CARDINAL trial in previously treated CML patients, with 38 participants evaluable for efficacy. TERN-701 achieved a major molecular response (MMR) rate of 75% at week 24, with 64% of patients reaching MMR overall in the dataset presented. The investigational agent also supported simple once-daily dosing without a food effect, improving convenience relative to many existing tyrosine kinase inhibitor (TKI) regimens.

SHERIDAN, WYOMING - December 11, 2025 - Mercedes-Benz is expanding its sustainability playbook with "Tomorrow XX", a cross-portfolio technology program designed to decarbonize vehicle components, scale circular materials and turn end-of-life cars into a strategic raw-materials source. For OEMs, suppliers and material innovators, the initiative signals how one of the world's leading premium automotive brands plans to industrialize low-carbon, circular design across its global lineup.

Holistic sustainability roadmap across the Mercedes-Benz portfolio

Tomorrow XX extends the holistic, multi-disciplinary approach first showcased in the VISION EQXX and CONCEPT AMG GT XX to the entire product portfolio, across all drivetrains. From the earliest design stages through to end-of-life, every component and material is being scrutinized for CO₂ impact, resource intensity and recyclability.

SHERIDAN, WYOMING - December 10, 2025 - Pfizer Inc. is expanding its cardiometabolic ambitions through an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical, to develop, manufacture and commercialize YP05002, an oral GLP-1 receptor agonist currently in Phase 1 for chronic weight management. The deal strengthens Pfizer's position in the fast-moving obesity field and adds a differentiated small-molecule asset to its portfolio of metabolic disease candidates.

Strategic Bet on Small-Molecule GLP-1 in Obesity

Under the agreement, China-based YaoPharma will complete an ongoing Phase 1 study of YP05002 before transferring global development and commercialization rights to Pfizer. For Pfizer, the asset fits neatly into a strategy that aims to pair novel mechanisms with scalable, oral delivery formats for obesity and adjacent cardiometabolic conditions.

SHERIDAN, WYOMING - December 10, 2025 - Pfizer Inc. is setting the stage for its next financial chapter with an analyst conference call and webcast on December 16, 2025, where the U.S.-based biopharmaceutical leader will present full-year 2026 financial guidance to investors and the broader market. The event underscores how large pharma companies use structured guidance cycles to frame expectations around revenue, R&D investment, pipeline execution and capital allocation.

Anchoring Investor Expectations with 2026 Guidance

Pfizer will host the live call with investment analysts at 8:00 a.m. EST on Tuesday, December 16, 2025, with a simultaneous webcast for global stakeholders. The primary objective is to provide formal full-year 2026 financial guidance, giving clarity on topline trends, margin expectations, R&D spending and the company's capital deployment priorities.

SHERIDAN, WYOMING - December 10, 2025 - Yupp Video Services (YVS), the B2B technology arm of YuppTV, is stepping up its role as a white-label OTT backbone provider by delivering a full-stack platform overhaul for Chaupal, one of India's fastest-growing regional streaming services for Punjabi, Haryanvi and Bhojpuri content. The partnership is designed to harden reliability, boost performance and modernize user experience as Chaupal enters its next aggressive growth phase.

Full Technology Replatforming for High-Growth Regional OTT

After three years of rapid subscriber expansion, Chaupal reached the limits of its existing technology stack and needed an infrastructure built for scale, multi-device reach and operational resilience. Yupp Video Services responded with a fully custom instance of its OTT platform tailored to Chaupal's regional content strategy and monetization model.

SHERIDAN, WYOMING - December 10, 2025 - TCL SunPower Global is expanding its European residential solar strategy with a new fully integrated home energy storage system designed to work natively with SunPower solar panels and the SunPower app, giving installers and homeowners a single-vendor ecosystem for generation, storage and digital energy management.

From Standalone Batteries to a Connected Home Energy Ecosystem

The new SunPower home energy storage system is positioned as the core of a connected domestic energy ecosystem rather than a standalone battery. By combining PV generation, storage and load control through one brand, one account and one app, TCL SunPower aims to simplify deployment and post-sale support for its installer partners while helping homeowners maximize self-consumption and energy independence.

SHERIDAN, WYOMING - December 10, 2025 - Implantica is strengthening its European market expansion for RefluxStop®, announcing that Florence's renowned Careggi University Hospital has performed its first procedure with the implantable device for gastroesophageal reflux disease (GERD), adding another high-profile reference center to the therapy's growing footprint.

Careggi University Hospital Becomes a Flagship Center for GERD Innovation

The first RefluxStop® implantation at Careggi University Hospital was carried out by Dr. Paolo Prosperi, Chief of Emergency Surgery, assisted by Dr. Alessio Giordano. As part of the University of Florence, Careggi is one of Italy's most respected academic medical centers and a key reference institution for advanced surgical technologies.

SHERIDAN, WYOMING - December 10, 2025 - Husqvarna Group is sharpening its long-term strategy to deliver profitable growth, unveiling new 2030 financial and sustainability targets and a transformational cost-out program as it positions its global outdoor equipment and robotics portfolio for higher margins and capital efficiency.

New 2030 Strategy Anchored in Portfolio Focus and Operational Excellence

At its Capital Markets Day in Stockholm, Husqvarna Group's leadership team briefed institutional investors, analysts and financial media on the next strategy period to 2030. The company will focus on strategic portfolio management, operational excellence and full leverage of its aftermarket offering across its core manufacturing and industry segments.

SHERIDAN, WYOMING - December 10, 2025 - SK Chemicals is moving to secure full control over its circular plastics value chain by vertically integrating feedstock sourcing through a new joint venture and Feedstock Innovation Center (FIC) in China, positioning its depolymerization-based chemical recycling business for stronger cost competitiveness and supply stability across Asia-Pacific.

From Depolymerization Pioneer to Fully Integrated Circular Plastics Player

SK Chemicals has signed a joint venture agreement with Shaanxi-based recycler Kelinle to build the Feedstock Innovation Center, a dedicated facility for processing waste plastics into recycled raw materials. Located on an idle 13,200 m² site in Weinan, Shaanxi Province, the FIC will convert end-of-life plastics into PET pellets that feed SK Chemicals' depolymerization process.

SHERIDAN, WYOMING - December 10, 2025 - VisIC Technologies has raised $26 million in a Round B financing that positions its Gallium Nitride (GaN) power devices at the center of the next wave of electric vehicle (EV) drivetrain innovation for global automotive and mobility markets. Led by a global semiconductor leader with Hyundai Motor Company and Kia (HKMC) joining as strategic investor, the funding will help VisIC industrialize its D³GaN™ platform for high-volume traction inverters and adjacent high-voltage applications.

GaN Steps Forward as EV OEMs Push Beyond Silicon and SiC

SHERIDAN, WYOMING - December 10, 2025 - Fresco is stepping up its ambition to become the default operating system for the smart kitchen, closing a €15 million Series C round to accelerate its AI-driven cooking platform for appliance manufacturers and their global consumer base. The Dublin-based company is positioning its KitchenOS and AI Cooking Companion as core infrastructure for appliance OEMs that want to deliver personalized, connected cooking experiences at scale.

From Smart Appliances to an AI-Driven Connected Kitchen Ecosystem

The latest funding round brings together mission-aligned investors focused on the future of food and connected living. New backers include Samuel Dennigan of Strong Roots, Barry Napier of Cubic3 and Tyler Hu of Arda, with continued support from existing investors such as Middleby, ACT Venture Capital, AE Ventures, Morpheus Ventures and Alsop Louie Partners.

SHERIDAN, WYOMING - December 10, 2025 - Hanwha Finance is sharpening its Middle East growth agenda as Chief Global Officer Dong-Won Kim used his opening address at Abu Dhabi Finance Week's Global Markets Summit to position South Korea-UAE financial collaboration as a long-term strategic pillar for both economies and a testbed for next-generation digital capital markets.

Strengthening a Korea-UAE "100-Year Partnership" Through Finance

Speaking in Abu Dhabi, Kim framed financial services as the connective tissue that will turn high-level Korea-UAE diplomacy into investable projects and new cross-border capital flows. He noted that "since the establishment of diplomatic relations in 1980, South Korea and the UAE have continuously expanded the scope of cooperation", and stressed that Hanwha Finance intends to help carry forward a "100-year partnership" between the two nations.

SHERIDAN, WYOMING - December 10, 2025 - Europe has taken a decisive step toward defence communications sovereignty with the successful over-the-air demonstration of the European Protected Waveform (EPW), validating a new generation of secure, resilient, multi-orbit military satellite communications across GEO and LEO.

Milestone trial proves resilience against jamming and cyber threats

Conducted on November 26-27, 2025 at Universität der Bundeswehr München in Germany, the EPW tests confirmed the waveform's ability to protect mission-critical links against jamming, cyber threats and unauthorised access. For defence ministries facing increasingly contested and congested spectrum, the results provide concrete evidence that next-generation protected satcom can be engineered on European soil and operated across both geostationary and non-geostationary constellations.